HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
Navigating 9 Analyst Ratings For United Therapeutics
United Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
H.C. Wainwright analyst Andrew Fein maintains $United Therapeutics(UTHR.US)$ with a buy rating, and adjusts the target price from $300 to $400.According to TipRanks data, the analyst has a success
United Therapeutics Analyst Ratings
Express News | United Therapeutics Corporation : H.c. Wainwright Raises Target Price to $400 From $300
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Is Now The Time To Put United Therapeutics (NASDAQ:UTHR) On Your Watchlist?
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $350
Wells Fargo analyst Tiago Fauth maintains $United Therapeutics(UTHR.US)$ with a buy rating, and maintains the target price at $350.According to TipRanks data, the analyst has a success rate of 42.1%
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $344
Leerink Partners analyst Roanna Ruiz maintains $United Therapeutics(UTHR.US)$ with a buy rating, and adjusts the target price from $338 to $344.According to TipRanks data, the analyst has a success
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing
Why United Therapeutics (UTHR) Is a Top Growth Stock for the Long-Term
Express News | United Therapeutics Corp : Leerink Partners Raises Target Price to $344 From $338
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
5 High ROE Stocks to Buy as Low Inflation Fuels Rate Cut Hopes
Is United Therapeutics (UTHR) a Solid Growth Stock? 3 Reasons to Think "Yes"
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings